NASDAQ:PHAR Pharming Group (PHAR) Stock Price, News & Analysis $12.35 +0.52 (+4.40%) Closing price 08/13/2026 04:00 PM EasternExtended Trading$11.98 -0.38 (-3.04%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pharming Group Stock (NASDAQ:PHAR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharming Group alerts:Sign Up Key Stats Today's Range$11.80▼$13.3250-Day Range$9.82▼$14.4152-Week Range$9.62▼$21.34Volume32,807 shsAverage Volume18,727 shsMarket Capitalization$874.13 millionP/E Ratio102.92Dividend YieldN/APrice Target$38.67Consensus RatingHold Company Overview Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins. The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe. RUCONEST represents the first recombinant C1 inhibitor therapy, offering an alternative to plasma-derived treatments and addressing key safety and supply concerns associated with conventional sources. Pharming continues to support RUCONEST through lifecycle management initiatives and expanded patient access programs. Beyond its marketed product, Pharming’s research and development pipeline includes additional indications for C1 esterase inhibitor in prophylactic HAE treatment and novel programs targeting other rare and genetic disorders. Preclinical efforts leverage the same transgenic expression platform to explore therapies for conditions such as alpha-1 antitrypsin deficiency and metabolic disorders. Strategic collaborations and licensing agreements underpin the company’s approach to expanding its portfolio and reaching underserved patient populations. Pharming Group serves patients and partners across Europe, North America, Latin America and Asia-Pacific through a combination of direct commercial operations and regional partnerships. The company is led by Chief Executive Officer Sijmen de Vries, whose experience in biotechnology and global product commercialization supports Pharming’s mission to deliver life-transforming therapies to individuals affected by rare diseases.AI Generated. May Contain Errors. Read More Pharming Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScorePHAR MarketRank™: Pharming Group scored higher than 75% of companies evaluated by MarketBeat, and ranked 174th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingPharming Group has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialPharming Group has a consensus price target of $38.67, representing about 213.1% upside from its current price of $12.35.Amount of Analyst CoveragePharming Group has only been the subject of 4 research reports in the past 90 days.Read more about Pharming Group's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth20.00% Earnings GrowthEarnings for Pharming Group are expected to grow by 20.00% in the coming year, from $0.25 to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharming Group is 102.92, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharming Group is 102.92, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 269.63.Price to Book Value per Share RatioPharming Group has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.03% of the float of Pharming Group has been sold short.Short Interest Ratio / Days to CoverPharming Group has a short interest ratio ("days to cover") of 1.98, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharming Group has recently increased by 92.99%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharming Group does not currently pay a dividend.Dividend GrowthPharming Group does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.46 News SentimentPharming Group has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Pharming Group this week, compared to 3 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharming Group insiders have not sold or bought any company stock.Percentage Held by Insiders2.07% of the stock of Pharming Group is held by insiders.Percentage Held by Institutions0.03% of the stock of Pharming Group is held by institutions.Read more about Pharming Group's insider trading history. Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAR Stock News HeadlinesPharming Group N.V.: Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderAugust 13 at 7:54 AM | finanznachrichten.dePharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderAugust 13 at 2:53 AM | markets.businessinsider.comNow that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was the trigger. Benedict, who delivered a 279% return on cash in 2025 across a 20-year winning streak, says the listing launched what he calls the 'Final Phase of Elon's Master Plan.' He's identified one specific ticker - not SpaceX, Tesla, or any Elon-affiliated company - that he believes could see billions in inflows as this phase unfolds. He calls it his trade of the year.August 14 at 1:00 AM | Brownstone Research (Ad)Pharming Group (PHAR) Stock Price, Quote, News & HistoryAugust 12 at 6:45 AM | benzinga.comPharming Group (PHAR) Securities Investigation Notice - Levi & KorsinskyAugust 7, 2026 | prnewswire.comSecurities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzAugust 5, 2026 | tmcnet.comSecurities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.August 5, 2026 | businesswire.comLevi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)August 5, 2026 | globenewswire.comSee More Headlines PHAR Stock Analysis - Frequently Asked Questions How have PHAR shares performed this year? Pharming Group's stock was trading at $17.67 at the beginning of the year. Since then, PHAR stock has decreased by 30.1% and is now trading at $12.35. How were Pharming Group's earnings last quarter? Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) announced its earnings results on Thursday, July, 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by $0.04. Pharming Group had a trailing twelve-month return on equity of 3.40% and a net margin of 2.51%. Read the conference call transcript. When did Pharming Group IPO? Pharming Group (PHAR) raised $0 in an IPO on Wednesday, December 23rd 2020. The company issued 899,802 shares at a price of $0.00 per share. How do I buy shares of Pharming Group? Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharming Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharming Group investors own include Pharming Group (PHGUF), Meta Platforms (META), NVIDIA (NVDA), Applied DNA Sciences (APDN), Costco Wholesale (COST). Company Calendar Last Earnings7/30/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 2 weeks, PHAR's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PHAR CIK1828316 Webwww.pharming.com Phone31-71-524-7400FaxN/AEmployees280Year Founded1988Price Target and Rating Average Price Target for Pharming Group$38.67 High Price Target$41.00 Low Price Target$37.00 Potential Upside/Downside+213.1%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.12 Trailing P/E Ratio102.92 Forward P/E Ratio49.40 P/E GrowthN/ANet Income$2.85 million Net Margins2.51% Pretax Margin4.31% Return on Equity3.40% Return on Assets1.90% Debt Debt-to-Equity Ratio0.34 Current Ratio3.01 Quick Ratio2.31 Sales & Book Value Annual Sales$376.13 million Price / Sales2.32 Cash Flow$0.21 per share Price / Cash Flow58.99 Book Value$3.82 per share Price / Book3.23Miscellaneous Outstanding Shares70,780,000Free Float69,313,000Market Cap$874.13 million OptionableNot Optionable Beta-0.01 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:PHAR) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHow the JPMorgan $8,000 Gold Call Exposed the Biggest Mistake in Most Retirement AccountsJPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
